Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims



    Explore by Goal












     Quick Explanation


    Ruqi Tang — science-strength snapshot
    Evidence quality review is constrained by missing full text/paper-level design details in the provided input. Based on the specific cited works visible here, her research appears concentrated in the gut–liver immunology / microbiome axis and genetics of cholestatic autoimmune liver disease, with several high-impact publications in major journals.



     Long Explanation


    Author Review: Ruqi Tang

    Skeptical, evidence-based critique using only the publications explicitly included in your input.

    1) What’s known from the provided dossier (and what is not)

    • Known (from provided input): Ruqi Tang is associated with publications spanning microbiome/immune mechanisms in liver disease and genetics risk loci/associations in primary biliary cholangitis (PBC). (Selection of concrete examples below.)
    • Not known here: The full experimental design, sample sizes, cohort composition, sequencing/analysis pipelines, effect sizes, validation strategies, and whether key claims replicate across independent cohorts—because only article metadata/abstract snippets were provided for the highlighted works.
    • Epistemic humility: Without method-level details, it is not possible to rigorously judge internal validity (bias, confounding, measurement error, multiple-testing control) for each specific claim in the cited papers.

    2) Publication themes visible in your input

    Primary clusters (qualitative, from paper titles/DOIs present):
    1. Gut microbial profile & bile acids in autoimmune cholestatic disease (e.g., PBC gut microbiome changes; bile acids interacting with microbiota).
    2. Gut–liver immunology & microbiome–autoimmunity paradigm (reviews and synthesis framing mechanisms in liver immunology).
    3. Host genetics of PBC risk via GWAS/meta-analysis and candidate loci/risk loci discovery (human genetics).

    3) Visualizations from the provided year-count series

    Note: This chart uses only the yearly works_count values that were explicitly included in your input.

    4) Concrete paper-level evidence: what these works suggest scientifically

    4.1 Gut microbiome state in PBC; partial restoration context
    A highlighted study titled “Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy” (Gut, 2017) reports comparative microbiome differences between PBC patients and healthy controls and examines a UDCA-therapy context described as “partially restored.”
    Skeptical critique (limits visible from metadata only):
    • Causality risk: Microbiome differences can be consequences of disease state, diet, medication, or inflammation; “restoration after UDCA” does not by itself prove microbiome causally drives clinical endpoints.
    • Confounding sensitivity: Without method-level details (sequencing depth, batch effects, covariate adjustment, longitudinal sampling), interpretability remains limited.
    4.2 Autoimmune hepatitis and the liver–microbiome axis
    Another highlighted article in Gut (2019) is “Alterations of gut microbiome in autoimmune hepatitis”, focusing on microbiome alterations in autoimmune hepatitis with the stated aim of leveraging a corticosteroids treatment-naïve group.
    Skeptical critique:
    • Selection bias risk: “treatment-naïve” helps, but other confounders (baseline disease severity, diet, sampling time, antibiotics history) can still drive microbiome differences.
    • Analysis risk: Microbiome inference is highly sensitive to bioinformatic pipelines; without pipeline transparency, results may not reproduce.
    4.3 Mechanistic synthesis in gut–liver immunology
    A review titled “The microbiome and autoimmunity: a paradigm from the gut–liver axis” (Cellular and Molecular Immunology, 2018) organizes mechanistic hypotheses (immune dysregulation linked to microbial and bile-acid-related processes).
    Skeptical critique:
    • Review-level uncertainty: Reviews summarize; they may reflect the field’s bias and the evidence base at publication time, and do not guarantee that all mechanistic links are equally supported.
    • Correlation/causation mismatch: Many microbiome findings remain correlational; a review may over-weight stronger mechanistic claims compared to evidence strength for human causality.
    4.4 Genetics: GWAS risk loci for primary biliary cholangitis
    A GWAS paper titled “A genome-wide association study identifies six novel risk loci for primary biliary cholangitis” (Nature Communications, 2017) reports discovery and replication in a Han Chinese cohort context with the goal of identifying novel PBC risk loci.
    Skeptical critique:
    • Population transferability: GWAS signals can be ancestry-specific; translation to other ethnicities needs independent validation.
    • Biological mechanism gap: GWAS loci often map to non-coding variants; mechanistic causality requires functional follow-up.

    5) Scientific strength (evidence-weighted, with explicit uncertainty)

    What looks strong
    • Topic coherence across methods: The presented set shows a coherent research arc spanning microbiome/bile-acid immune interactions and human genetics of autoimmune cholestatic disease. (Examples: ; ; )
    • Engagement with both observational & risk-architecture evidence: Combining human cohort microbiome studies and genetics improves the chance of convergent mechanistic models—though each still has its own validity threats.
    What remains uncertain / potential blind spots
    • Human microbiome causality is fragile: Many microbiome results are correlational and sensitive to confounding (diet, medication, sampling, batch effects). Even “post-therapy restoration” framing does not establish causal direction without rigorous longitudinal mediation or mechanistic perturbation.
    • Functional interpretation gap: For GWAS loci, associational signals often require downstream functional mapping; without that, the risk loci may not translate to mechanistic levers.
    • Selection of papers in your input: This dossier highlights specific works; a thorough evaluation needs the full publication list and paper-by-paper method scrutiny (including negative/failed studies when available).
    Confidence level
    Moderate confidence about the research area coherence and types of evidence represented, but low confidence about fine-grained rigor of each study’s internal validity because full methods and key statistics were not provided in your input.

    6) Fast “what would disprove/change this view?” checklist

    • Independent replication failures for the microbiome–disease associations across cohorts with rigorous covariate matching.
    • Re-analysis showing that key microbiome signals collapse after correcting for batch effects, sequencing depth, or compositional artifacts.
    • GWAS loci that fail replication in other ancestries or show no plausible functional pathway upon fine-mapping and functional assays.
    • Evidence that supposed therapy-associated “restoration” is explained by differential sampling times, concurrent medications, or other treatment co-interventions rather than UDCA-specific effects.

    Run a full evidence audit with an AI scientist agent

    The agent can iteratively pull and scrutinize the paper-level methods behind the listed works (not just abstracts/metadata) and produce a stricter bias/replication/causality assessment.


    Feedback:    

    Updated: May 01, 2026

     Analysis Wizard



    It downloads and parses the provided paper metadata, then builds a prioritized evidence map (microbiome vs bile-acid vs genetics) to flag replication- and confounding-sensitive claims for each study.



     Hypothesis Graveyard


    “Microbiome differences are the primary cause of PBC in all patients”: could be overturned if stratified analyses show microbiome signatures track disease severity or treatment rather than preceding onset.


    “GWAS risk loci directly specify causal microbial taxa”: unlikely if fine-mapping doesn’t implicate microbiome-relevant functional pathways or if taxa associations fail in replication with proper confounding control.

     Science Art


    Author Review: Ruqi Tang Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending